Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

• Autori principali: Isla D (Autore), De Castro J (Autore), Juan O (Autore), Grau S (Autore), Orofino J (Autore), Gordo R (Autore), Rubio-Terrés C (Autore), Rubio-Rodríguez D (Autore)
• Natura: Libro
• Pubblicazione: Dove Medical Press, 2016-12-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Dolores Isla,1 Javier De Castro,2 Oscar Juan,3 Santiago Grau,4 Javier Orofino,5 Rocío Gordo,5 Carlos Rubio-Terrés,6 Darío Rubio-Rodríguez6 1Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza, 2Medical Oncology Department, Universitary Hospital La Paz, Madrid, 3Medical...